MAGA, the way I see it is that CytoDyn is an investment by PAUL for their clients and what is interesting is their bio technology is similar to ENZC. By PAUL accumulating ENZC is just another validation of a potential great investment as determined by their own standards. It proves that large investments are being made by institutions and not just retail. The question is who are they buying ENZC for.
News 
Market Data 
Discover 
